PL346011A1 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
PL346011A1
PL346011A1 PL99346011A PL34601199A PL346011A1 PL 346011 A1 PL346011 A1 PL 346011A1 PL 99346011 A PL99346011 A PL 99346011A PL 34601199 A PL34601199 A PL 34601199A PL 346011 A1 PL346011 A1 PL 346011A1
Authority
PL
Poland
Prior art keywords
coadministration
acat
treatment
atherosclerotic lesions
mmp inhibitors
Prior art date
Application number
PL99346011A
Other languages
English (en)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PL346011A1 publication Critical patent/PL346011A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PL99346011A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions PL346011A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
PL346011A1 true PL346011A1 (en) 2002-01-14

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99346011A PL346011A1 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (cs)
JP (1) JP2002521328A (cs)
KR (1) KR20010083134A (cs)
CN (1) CN1310629A (cs)
AP (1) AP2001002035A0 (cs)
AU (1) AU4701799A (cs)
BG (1) BG105162A (cs)
BR (1) BR9912296A (cs)
CA (1) CA2335062A1 (cs)
CZ (1) CZ2001126A3 (cs)
EA (1) EA200100153A1 (cs)
EE (1) EE200100046A (cs)
HR (1) HRP20010055A2 (cs)
HU (1) HUP0102880A3 (cs)
ID (1) ID30030A (cs)
IL (1) IL140982A0 (cs)
IS (1) IS5809A (cs)
NO (1) NO20010291D0 (cs)
OA (1) OA11584A (cs)
PL (1) PL346011A1 (cs)
SK (1) SK502001A3 (cs)
TR (1) TR200100205T2 (cs)
WO (1) WO2000004892A2 (cs)
YU (1) YU3501A (cs)
ZA (1) ZA200100294B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
NZ524406A (en) * 2000-09-01 2004-06-25 Sankyo Co Medicinal compositions containing HMG-CoA reductase inhibitor and ACAT inhibitor
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
BR0308908A (pt) * 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
CA2492035A1 (en) * 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CA2221729A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
DE69707865T2 (de) * 1996-05-17 2002-05-02 Warner-Lambert Co., Morris Plains Biphenylsulfonamid matrix metalloproteinase inhibitoren
BR9711988A (pt) * 1996-09-04 1999-08-24 Warner Lambert Co Inibidores de metaloproteinase de matriz e seus empregos terap-uticos

Also Published As

Publication number Publication date
OA11584A (en) 2004-07-20
CA2335062A1 (en) 2000-02-03
JP2002521328A (ja) 2002-07-16
BG105162A (en) 2001-12-29
CZ2001126A3 (cs) 2002-01-16
HUP0102880A2 (en) 2002-06-29
KR20010083134A (ko) 2001-08-31
ID30030A (id) 2001-11-01
ZA200100294B (en) 2002-01-10
HRP20010055A2 (en) 2002-04-30
EA200100153A1 (ru) 2001-08-27
IL140982A0 (en) 2002-02-10
AU4701799A (en) 2000-02-14
IS5809A (is) 2001-01-12
WO2000004892A2 (en) 2000-02-03
NO20010291L (no) 2001-01-18
WO2000004892A3 (en) 2000-05-18
EP1098662A2 (en) 2001-05-16
CN1310629A (zh) 2001-08-29
HUP0102880A3 (en) 2002-11-28
SK502001A3 (en) 2002-06-04
TR200100205T2 (tr) 2001-05-21
AP2001002035A0 (en) 2001-03-31
NO20010291D0 (no) 2001-01-18
BR9912296A (pt) 2001-04-17
YU3501A (sh) 2005-06-10
EE200100046A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
EP1100392A4 (en) METHODS AND DEVICES FOR REDUCING THE MINERAL CONTENT OF VASCULAR CALCIFIED LESIONS
HUP0101613A3 (en) Metalloprotease inhibitor (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides and medicaments containing the same
SI1133477T1 (en) Substituted benzimidazoles and their use as parp inhibitors
HUP0004592A3 (en) Compounds and methods for the inhibition of the expression of vcam-1
AU2212299A (en) Compositions and methods for the treatment of tumor
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
HU0900792D0 (en) Use of renin-angiotensin inhibitors
PL341335A1 (en) Combination of ace and mmp inhibitors
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
GB2342045B (en) Mineral and vitamin combinations for the treatment of stress and allergies
IL127496A0 (en) The use of MMP inhibitors for the treatment of ocular angiogenesis
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
HUP0102880A3 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IL143212A0 (en) Compositions and methods for the treatment of tumor
GB9924626D0 (en) Semiconductor device and method of forming the same
GB9806287D0 (en) Monobactam enzyme inhibitors
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
PL348029A1 (en) Fluticasone lotion having improved vasoconstrictor activity
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis
AU1940800A (en) Combination therapy for the treatment of sepsis
AU1292000A (en) Device and method for the direct reduction of iron oxides
EP1135141A4 (en) PHOSPHOLIPASE INHIBITORS FOR TREATING CANCER